Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
China SXT Pharmaceuticals Inc (SXTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SXTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $0
Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.39% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.57M USD | Price to earnings Ratio 0.01 | 1Y Target Price - |
Price to earnings Ratio 0.01 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.1 | 52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 |
52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 124.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 318.69% | Operating Margin (TTM) -76.95% |
Management Effectiveness
Return on Assets (TTM) 18.15% | Return on Equity (TTM) 57.63% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value 190144853 | Price to Sales(TTM) 109.75 |
Enterprise Value 190144853 | Price to Sales(TTM) 109.75 | ||
Enterprise Value to Revenue 104.57 | Enterprise Value to EBITDA 29.92 | Shares Outstanding 116028000 | Shares Floating 488309 |
Shares Outstanding 116028000 | Shares Floating 488309 | ||
Percent Insiders 0.02 | Percent Institutions 0.01 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
China SXT Pharmaceuticals Inc
Company Overview
History and Background
China SXT Pharmaceuticals Inc. was founded to develop and manufacture Traditional Chinese Medicine (TCM) products. It focuses on creating high-quality, standardized TCM formulations, catering to the growing demand for natural and traditional healthcare solutions. Details on its exact founding year and significant milestones are limited in readily available public information.
Core Business Areas
- TCM Products Manufacturing: Manufacturing and distribution of various Traditional Chinese Medicine products, including granules, powders, capsules, and tablets.
- Product Development: Research and development of new TCM formulations and improvement of existing products.
- Distribution and Sales: Sales and distribution of TCM products through pharmacies, hospitals, and distributors.
Leadership and Structure
Information on the specific leadership team and organizational structure of China SXT Pharmaceuticals Inc. is not readily available in comprehensive detail in common public sources.
Top Products and Market Share
Key Offerings
- Concentrated TCM Granules: SXT's primary product line focuses on concentrated TCM granules, which are convenient and easy-to-consume forms of traditional herbal remedies. Market share data for these granules is not readily available; however, they face competition from other TCM manufacturers and distributors. The competitors are unknown due to a lack of company public data. Revenue from this product is also unknown
- TCM Powders and Capsules: The company also offers TCM products in powder and capsule form. These are often customized formulations based on individual patient needs. Market share is not readily available and competitors for TCM powders and capsules are various TCM manufacturing companies and herbal medicine providers. Revenue from this product is also unknown.
Market Dynamics
Industry Overview
The Traditional Chinese Medicine industry is experiencing growth due to increasing global interest in alternative medicine and natural healthcare solutions. Demand is driven by a growing aging population and rising healthcare costs.
Positioning
China SXT Pharmaceuticals Inc. aims to position itself as a provider of high-quality, standardized TCM products, focusing on product innovation and distribution channel expansion.
Total Addressable Market (TAM)
The global TCM market is estimated to be in the billions of dollars. China SXT Pharmaceuticals Inc is positioned to capture a share of this market through its focus on standardized products and expanding its distribution network. However, the company's actual TAM capture is unknown because the total market value is unknown.
Upturn SWOT Analysis
Strengths
- Established TCM Manufacturing Capabilities
- Focus on Standardized TCM Formulations
- Distribution Network in China
- Product Development Capabilities
Weaknesses
- Limited Brand Recognition Outside of China
- Dependence on the Chinese Market
- Lack of Detailed Financial Transparency
- Concentration on TCM, limiting product diversification
Opportunities
- Expansion into International Markets
- Development of New TCM Products
- Strategic Partnerships with Healthcare Providers
- Increased Focus on E-commerce Sales
Threats
- Regulatory Changes in China
- Competition from Established TCM Manufacturers
- Fluctuations in Raw Material Prices
- Negative Publicity Regarding TCM Efficacy
Competitors and Market Share
Key Competitors
Competitive Landscape
Without specific competitors and financial data, an evaluation of China SXT Pharmaceuticals Incu2019s advantages and disadvantages compared to its competitors is not possible.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are difficult to assess due to the lack of comprehensive financial data. Publicly available information limits the assessment of historical growth trends.
Future Projections: Future growth projections based on analyst estimates are unavailable due to limited analyst coverage.
Recent Initiatives: Information on recent strategic initiatives is limited in publicly accessible sources.
Summary
China SXT Pharmaceuticals Inc. is focused on manufacturing and distributing TCM products, primarily in China. Lack of financial data limits a thorough analysis, but it focuses on standardizing TCM formulations. Regulatory changes and competition within the TCM industry pose potential challenges. Strategic expansion and product innovation are essential for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports (Limited)
Disclaimers:
The analysis provided is based on limited publicly available information. Financial data and market share information may not be fully accurate or up-to-date. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China SXT Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-01-04 | Chairman of the Board & Co-CEO Mr. Feng Zhou | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 75 | Website https://www.sxtchina.com |
Full time employees 75 | Website https://www.sxtchina.com | ||
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.